Arcturus Therapeutics Holdings Inc. ARCT is engaged in developing messenger RNA (mRNA) medicines and vaccines based on its innovative and enabling technologies. San Diego, CA-based Arcturus has ...

After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class I CF participants exhibited encouraging reduction of mucus plug number and mucus volume 12-week study enrolling up to 20 CF ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism (35% comfortable with technology) and challenges translating success ...

Arcturus is executing well, utilizing strategic partnerships with CSL and Meiji to de-risk its financial position. The company has reinforced its management team by appointing a CMO and CDO, bringing ...

A new COVID variant Arcturus has caused a huge uptick in infections in India. (Reuters) Five people in England have died from the new COVID variant dubbed Arcturus, the UK Health Security Agency ...